Friday 6 November 2026 Export PHIO’s income statement to Excel — free account

Phio Pharmaceuticals Corp.

PHIO Healthcare Biotechnology

EPS: +20.0%
Free cash flow: −58.7%

Quarter to June 2026, against a year earlier

Insider buying

0.80 0.07 −8.05%

Follow PHIO

Alert me

Market cap: $9.3M
P/E: 0.0×
Fwd P/E: −1.4×
Dividend yield: —
F-score: 1/9
Altman Z: −18.25
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Bought, $m 0.08

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	2	—	—	—	—	—	1	—	2	4	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 15.04%

Capital & Financial Ratios $m

Size

Market Cap 9.30

Revenue ttm 0.14

Net income ttm (12.90)

Free cash flow ttm (12.21)

Net debt Q (13.00)

Valuation

P/E 0.00

Forward P/E (1.40)

Price / sales 68.34

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.74

Financial health

Current ratio Q 8.39

Debt / equity Q 0.00

Interest coverage Q —

Growth

Revenue growth Q −8.70%

Operating income growth Q −84.84%

EPS, this year +0.34%

EPS, next year A +57.79%

Revenue, next year A −100.00%

EPS, past 5 yrs —

EPS, next 5 yrs A +59.13%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 47.38%

10-year low 10-year high

P/B against its own 10 years 47.89%

10-year low 10-year high

EV/FCF against its own 10 years 24.23%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	8	5	21	13
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	9	6	21	14

	2023	2024	2025	Q'26
Payables	1	0	0	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	2	1	1	2

Compound Annual Growth %

	10y	5y	3y
Sales	—	(21.62%)	3.39%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	8.53%	9.13%	22.96%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.36 Actual −0.36

−0.49 −0.40 −0.30 −0.20 −0.10

Q3 FY25 Beat +0.01

Q4 FY25 Beat +0.19

Q1 FY26 Miss −0.10

Q2 FY26 Met 0.00

Q3 FY26 — Nov 12

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q3 FY25	−0.45	−0.44	Beat by 0.01
Q4 FY25	−0.34	−0.15	Beat by 0.19
Q1 FY26	−0.24	−0.34	Miss by 0.10
Q2 FY26	−0.36	−0.36	Met by 0.00
Q3 FY26	−0.36	—	Reports 12 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.34)	(0.36)	—	—	—
’25	(0.41)	(0.45)	(0.44)	(0.25)	(1.45)
’24	(4.23)	(3.62)	(1.54)	(1.43)	(9.08)
’23	(28.35)	(13.23)	(10.26)	(5.64)	(46.80)
’22	(20.53)	(20.53)	(28.09)	(21.56)	(90.91)
’21	(34.58)	(21.61)	(30.25)	(27.01)	(112.38)
’20	(143.71)	(36.74)	(43.22)	(44.30)	(207.46)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’19	0	—	—	—	0
’18	0	0	0	0	0
’17	—	—	—	—	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(4)	—	—	—
’25	(1)	(3)	(2)	(2)	(8)
’24	(2)	(2)	(2)	(1)	(7)
’23	(3)	(3)	(3)	(2)	(11)
’22	(3)	(2)	(4)	(3)	(12)
’21	(3)	(3)	(3)	(2)	(12)
’20	(2)	(2)	(2)	(3)	(9)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(4)	—	—	—
’25	(1)	(3)	(2)	(2)	(8)
’24	(2)	(2)	(2)	(1)	(7)
’23	(3)	(3)	(3)	(2)	(11)
’22	(4)	(2)	(4)	(3)	(12)
’21	(3)	(3)	(3)	(2)	(12)
’20	(2)	(2)	(2)	(3)	(9)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	0	0	0	0	—	—	—	—	—	—	0		+3.4%	—	—	—	—
	Gross margin, %	100.00	100.00	100.00	100.00	0.00	0.00	0.00	—	—	—	0.00		(100.0) pt	Powerpack Phio Pharmaceuticals Corp.’s next three years, line by line See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(9)	(14)	(7)	(9)	(9)	(13)	(11)	(11)	(7)	(9)	(13)		(0.4%)
	EBT margin, %	(47,336.84)	(93,820.00)	(5,333.33)	(42,419.05)	0.00	0.00	0.00	0.00	0.00	0.00	0.00		+47,336.8 pt
	Net income	(9)	(12)	(7)	(9)	(9)	(13)	(11)	(11)	(7)	(9)	(13)		(0.4%)
Per share, $
Per share, $	Revenue	167.30	37.50	115.00	4.88	0.00	0.00	0.00	0.00	0.00	0.00	0.00		n/m
	Earnings	(97,475.40)	(32,772.43)	(6,174.51)	(2,088.68)	(207.46)	(112.38)	(90.91)	(46.80)	(9.08)	(1.45)	(1.39)		(70.9%)
	Cash flow	(68,327.90)	(23,785.00)	(6,266.67)	(2,010.47)	(207.11)	(99.81)	(96.03)	(46.33)	(9.04)	(1.33)	(1.05)		(70.0%)
	Capex	(35.22)	(507.50)	(4.17)	(16.74)	(0.45)	(0.43)	(0.96)	(0.02)	0.01	0.00	0.00		(66.3%)
	Free cash flow	(68,363.12)	(24,292.50)	(6,270.83)	(2,027.21)	(207.55)	(100.24)	(96.99)	(46.35)	(9.03)	(1.34)	(1.05)		(70.0%)
	Book value	95,579.82	4,582.50	11,315.00	1,336.74	306.28	184.61	85.81	33.32	6.00	3.37	1.08		(68.0%)
	Shares, m	0	0	0	0	0	0	0	0	1	6	9		+234.7%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	—	—	—	—	—	—	0.00		0.0
	P/S	63.85	195.07	17.04	32.12	—	—	—	—	—	—	68.34		77.0
	P/B	0.58	7.13	0.17	0.76	—	—	—	—	—	—	0.74		2.2
	EV/Sales	(129.52)	140.88	(91.14)	(16.21)	—	—	—	—	—	—	(25.52)		(24.0)
	EV/FCF	1.12	(0.97)	1.63	0.25	—	—	—	—	—	—	0.28		0.5
Cash, $m
Cash, $m	Operating cash flow	(8)	(10)	(8)	(9)	(9)	(12)	(12)	(11)	(7)	(8)	(12)		+0.3%
	Capex	0	0	0	0	0	0	0	0	0	0	0		+13.0%
	Free cash flow	(8)	(10)	(8)	(9)	(9)	(12)	(12)	(11)	(7)	(8)	(12)		+0.3%
Balance, $m
Balance, $m	Working capital	11	2	13	5	13	22	11	8	5	20	13		+7.4%
	Net debt	(13)	(4)	(15)	(7)	(14)	(24)	(12)	(8)	(5)	(21)	(13)		+5.5%
	Shareholders’ equity	11	2	14	6	13	22	11	8	5	20	13		+7.1%
Returns, %
Returns, %	ROA	(90.15)	(142.35)	(75.80)	(76.26)	(73.97)	(64.96)	(60.45)	(97.63)	(94.69)	(63.90)	(100.78)		+26.2 pt
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0 pt
	ROE	(136.49)	(271.79)	(95.52)	(92.19)	(93.73)	(76.04)	(70.06)	(116.61)	(114.83)	(69.95)	(113.71)		+66.5 pt
People
People	Employees	15	15	9	11	10	12	10	9	5	6	—		(9.7%)
	Revenue/emp, $m	0.00	0.00	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2019 · latest quarter Mar 2019 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PTN Palatin Technologies, Inc.	$10.7M	12.2×	0.2×	−14.06% (below 0%: shrinking)	n/m	+34.21% (above 0%: growing)	100.00%	(1,469.35%)	Compare
AZR Azora Therapeutics, Inc.	$10.6M	— (loss-making)	—	—	n/m	−263.66% (below 0%: shrinking)	0.00%	0.00%	Compare
GDTC CytoMed Therapeutics Limited	$10.5M	— (loss-making)	— (loss-making)	—	n/m	−27.39% (below 0%: shrinking)	0.00%	—	Compare
PHIO Phio Pharmaceuticals Corp.	$10.1M	— (loss-making)	— (loss-making)	−8.70% (below 0%: shrinking)	n/m	−58.67% (below 0%: shrinking)	0.00%	0.00%
GTBP GT Biopharma, Inc.	$10.0M	0.8×	—	−100.00% (below 0%: shrinking)	n/m	−41.34% (below 0%: shrinking)	0.00%	0.00%	Compare
BLRX BioLineRx Ltd.	$9.3M	— (loss-making)	— (loss-making)	−3.29% (below 0%: shrinking)	n/m	−1,827.71% (below 0%: shrinking)	79.93%	(1,215.31%)	Compare
TPST Tempest Therapeutics, Inc.	$9.3M	— (loss-making)	—	−71.57% (below 0%: shrinking)	n/m	+67.04% (above 0%: growing)	0.00%	0.00%	Compare
CALC CalciMedica Inc.	$9.2M	— (loss-making)	—	—	n/m	+31.42% (above 0%: growing)	0.00%	0.00%	Compare
INAB IN8bio, Inc.	$9.2M	— (loss-making)	—	—	n/m	−1.30% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$9.6M	—	—	−42.82%	—	−14.34%	0.00%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 14 August 2026

Chief executive’s pay

Year	Total pay	Actually paid	$100 invested
2025	1.16m	885.95k	19.33
2024	387.02k	384.55k	23.25
2023	437.89k	379.39k	6.33

Ownership

Directors and executive officers, together 3.52%

CVI Investments, Inc. 9.99%

Intracoastal Capital LLC 9.10%

Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Phio Pharmaceuticals Corp. (PHIO) Latest News

5 Nov

Impact 3 · 4:05 PM · TMX Newsfile

Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation

19 Oct

Impact 3 · 9:53 AM · TMX Newsfile

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

13 Oct

Impact 4 · 7:00 AM · TMX Newsfile

Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance

23 Sep

Impact 3 · 7:00 AM

Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference

14 Sep

Impact 4 · 7:00 AM

Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma

11 Aug

Impact 3 · 7:00 AM

Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894

6 Aug

Impact 3 · 4:05 PM

Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

15 Jul

Impact 3 · 11:06 AM · InvestorsHub

Phio Pharmaceuticals Expands Global Patent Portfolio With New International Patent Milestones

Impact 3 · 7:00 AM

Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision

24 Jun

Impact 4 · 7:00 AM · TMX Newsfile

Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762

7 May

Impact 3 · 4:05 PM · TMX Newsfile

Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

30 Mar

Impact 4 · 7:00 AM · TMX Newsfile

Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762

23 Mar

Impact 4 · 7:00 AM · TMX Newsfile

Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement

16 Mar

Impact 4 · 11:30 AM · TMX Newsfile

Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office

5 Mar

Impact 3 · 4:05 PM · TMX Newsfile

Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update

19 Feb

Impact 4 · 7:00 AM · TMX Newsfile

Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894

10 Feb

Impact 4 · 7:00 AM · TMX NewsfileMT NewswiresMarketBeatMT NewswiresBioPharma DiveMarketBeatClinical Trials ArenaClinical Trials Arena

Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial

Impact 3 · 10:30 AM · Associated Press Finance

BC-Most Active Stocks

20 Jan

Impact 4 · 9:30 AM · TMX Newsfile

Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial

23 Dec

Impact 4 · 8:45 AM · Newsfile

Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762

25 Nov

Impact 4 · 11:30 AM

Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762

17 Nov

Impact 3 · 8:45 AM · Newsfile

Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress

13 Nov

Impact 3 · 4:15 PM · Newsfile

Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

7 Nov

Impact 4 · 10:30 AM · Newsfile

Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762

Impact 4 · 7:45 AM · Newsfile

Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program

3 Nov

Impact 4 · 7:45 AM · Newsfile

Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial

Impact 3 · 1:40 PM

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds

Impact 3 · 10:30 AM · Associated Press Finance

BC-Most Active Stocks

31 Oct

Impact 3 · 10:15 AM · Newsfile

Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

18 Sep

Impact 3 · 7:45 AM

Phio Pharmaceuticals to Present at the Life Sciences Future Conference

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Phio Pharmaceuticals Corp. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 14 August 2026

Chief executive’s pay

Ownership

Phio Pharmaceuticals Corp. (PHIO) Latest News

5 Nov

19 Oct

13 Oct

23 Sep

14 Sep

11 Aug

6 Aug

15 Jul

24 Jun

7 May

30 Mar

23 Mar

16 Mar

5 Mar

19 Feb

10 Feb

20 Jan

23 Dec

25 Nov

17 Nov

13 Nov

7 Nov

3 Nov

31 Oct

18 Sep

Stockrow Weekly